Summary
Cancer Research Technology Ltd (CRT) a subsidiary of Cancer Research UK, formerly Cancer Research Campaign Technology Ltd, is a research organization that develops and commercializes discoveries for treatment in the areas of cancer. The organization’s services include project development, drug discovery, commercialization, clinical development, imaging and funding. It address needs in cancer through initiatives such as CDP and the theme-based approach of CRT-DL. CRT provides commercialization services to oncology institutes worldwide, and also operates drug discovery laboratories. The organization operates through pharmaceutical companies, clinical and academic institutions, and biotechnology companies. It also operates in Massachusetts, the US and Cambridge, the UK. CRT is headquartered in London, the UK.
Cancer Research Technology Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Cancer Research Technology Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
GammaDelta Therapeutics Raises Funds through Seed Financing 16
ADC Therapeutics To Raise US$50 Million In Venture Financing 17
BliNK Therapeutics Secures US$1.78 Million In Seed Financing 18
Partnerships 19
Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 19
Artios Pharma Research Agreement with Cancer Research Technology 20
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 21
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 21
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 22
Medivir Enters into Development Agreement with Cancer Research Technology 23
BioInvent and CRT Enter into Research Agreement with University of Southampton 24
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 25
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 26
Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 27
GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 28
HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 29
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 30
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 31
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 32
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 33
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 34
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 36
Cancer Research Technology And AstraZeneca Extend Co-Development Agreement For Anti-Cancer Drugs 37
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 38
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 39
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 40
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 42
Cancer Research UK Enters Into Co-Development Agreement With Centella Therapeutics And Cancer Research Technology 43
Cancer Research Technology, Institute of Cancer Research And ZoBio Enter Into Agreement To Develop Cancer Drugs 44
MdxHealth Enters Into Co-Development Agreement With Newcastle University, Cancer Research Technology And Pfizer 46
Licensing Agreements 47
Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 47
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 48
Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 49
Merck Enters into Licensing Agreement with Cancer Research Technology 50
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 51
Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 52
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 53
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 54
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 55
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 56
Cancer Research Technology Enters Into Licensing Agreement With Cancer Therapeutics For FAK Inhibitor Portfolio 57
Affitech Enters Into Licensing Agreement With Cancer Research Technology 58
Cancer Research Technology Ltd - Key Competitors 60
Key Employees 61
Locations And Subsidiaries 62
Head Office 62
Other Locations & Subsidiaries 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63
List of Tables
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Cancer Research Technology Ltd, Deals By Therapy Area, 2011 to YTD 2017 10
Cancer Research Technology Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
GammaDelta Therapeutics Raises Funds through Seed Financing 16
ADC Therapeutics To Raise US$50 Million In Venture Financing 17
BliNK Therapeutics Secures US$1.78 Million In Seed Financing 18
Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 19
Artios Pharma Research Agreement with Cancer Research Technology 20
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 21
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 21
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 22
Medivir Enters into Development Agreement with Cancer Research Technology 23
BioInvent and CRT Enter into Research Agreement with University of Southampton 24
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 25
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 26
Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 27
GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 28
HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 29
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 30
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 31
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 32
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 33
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 34
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 36
Cancer Research Technology And AstraZeneca Extend Co-Development Agreement For Anti-Cancer Drugs 37
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 38
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 39
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 40
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 42
Cancer Research UK Enters Into Co-Development Agreement With Centella Therapeutics And Cancer Research Technology 43
Cancer Research Technology, Institute of Cancer Research And ZoBio Enter Into Agreement To Develop Cancer Drugs 44
MdxHealth Enters Into Co-Development Agreement With Newcastle University, Cancer Research Technology And Pfizer 46
Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 47
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 48
Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 49
Merck Enters into Licensing Agreement with Cancer Research Technology 50
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 51
Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 52
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 53
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 54
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 55
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 56
Cancer Research Technology Enters Into Licensing Agreement With Cancer Therapeutics For FAK Inhibitor Portfolio 57
Affitech Enters Into Licensing Agreement With Cancer Research Technology 58
Cancer Research Technology Ltd, Key Competitors 60
Cancer Research Technology Ltd, Key Employees 61
Cancer Research Technology Ltd, Other Locations 62
Cancer Research Technology Ltd, Subsidiaries 62
List of Figures
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Cancer Research Technology Ltd, Medical Devices Deals, 2011 to YTD 2017 11
